X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
VE202 is a first-in-class, orally administered, investigational live biotherapeutic product (LBP) consortium consisting of 16 strains of bacteria, which is investigated for the treatment of ulcerative colitis.
Lead Product(s): VE202,Vancomycin Hydrochloride
Therapeutic Area: Gastroenterology Product Name: VE202
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Vedanta Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen. Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021.
Lead Product(s): VE202
Therapeutic Area: Gastroenterology Product Name: VE202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
Details:
Vedanta intends to use the proceeds to fund a Phase 2 study of VE202 in inflammatory bowel disease (IBD), which it plans to initiate in 2021.
Lead Product(s): VE202
Therapeutic Area: Gastroenterology Product Name: VE202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 12, 2021
Details:
The new UEG Week data presentation focuses on the kinetics and durability of colonisation from an 11-strain consortium of VE202 under various dosing and pre-treatment regimens.
Lead Product(s): VE202
Therapeutic Area: Gastroenterology Product Name: VE202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: PureTech Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
Proceeds from the financing will supoorts company's ongoing effort in advancing Phase 1 studies in healthy volunteers of VE202, the Company’s orally-administered live biotherapeutic product (LBP) candidate for inflammatory bowel disease (IBD).
Lead Product(s): VE202
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: JSR Life Sciences
Deal Size: $71.1 million Upfront Cash: Undisclosed
Deal Type: Series C Financing June 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
